# Obio Technology (Shanghai)

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/obio-technology-shanghai-corp

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.oobio.com.cn
- Total disclosed funding: $77M
- Latest round: Series C (Dec 9, 2020)
- Investors on record: 11

## About

Established in 2013 and based in Shanghai, China, Obio Technology (Shanghai) Corp.,Ltd. operates as a biopharmaceutical company that focuses on gene therapy field. The company has many subsidiaries, such as OBiO Neuron (Shanghai) Biotechnology Co., Ltd., OBiO Join Translational (Shenzhen) Gene Technology Co., Ltd., and OBiO Intelli-M (Shanghai) Gene Technology Co., Ltd. The company established gene therapy manufacturing platform (GMP) in 2016. QuaCell Biotechnology has become the strategic partner of the company in March 2021. The company passed ISO9001:2015 quality management system certification.

The company provides contract research organization (CRO) service, such as gene therapy vector development, gene function research, drug target and efficacy research. The company also provides contract development and manufacturing organization (CDMO) service, such as process development and testing, IND-CMC pharmaceutical research, clinical samples GMP production. The company's platform provides holistic CDMO services for scientists, research facilities and medical institutions. The company's products include plasmid, adeno-associated virus, lentivirus and cell therapy products.

## Funding rounds

- Series C, Dec 9, 2020, $15M — Tencent Investment
- Series C, Sep 23, 2020, $44M — 5Y Capital, GP Capital, Loyal Valley Capital, Shanhai Capital, BioTrack Capital, Sherpa Healthcare Partners, Shanghai Lingang Capital
- Series B, Mar 6, 2020, $14M — GP Capital, Sinowisdom, Efung Capital
- Series A, Mar 1, 2015, $3.2M — Sinowisdom, HY Energy Group

## Investors

- Sinowisdom (https://capitalatlas.ai/funds/sinowisdom) — Series A, Series B
- HY Energy Group — Series A
- GP Capital (https://capitalatlas.ai/funds/gp-capital) — Series B, Series C
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series B
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series C
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series C
- Shanhai Capital (https://capitalatlas.ai/funds/shanhai-capital) — Series C
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series C
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series C
- Shanghai Lingang Capital — Series C
- Tencent Investment — Series C